Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer

• Published in: Cancers Vol. 15; no. 6; p. 1691
• Main Authors: Lugtenberg, Rieneke T, de Groot, Stefanie, Houtsma, Danny, Dezentjé, Vincent O, Vulink, Annelie J E, Fischer, Maarten J, Portielje, Johanneke E A, van der Hoeven, Jacobus J M, Gelderblom, Hans, Pijl, Hanno, Kroep, Judith R
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2023; MDPI
• Subjects: Adjuvants, Pharmaceutic; Antitumor agents; Breast cancer; Cancer therapies; Chemotherapy; Complications and side effects; Corticosteroids; Dexamethasone; Diabetes; Docetaxel; Dosage; Dosage and administration; Drug allergy; Drug therapy; Edema; Feasibility studies; Hypersensitivity; hypersensitivity reactions; Medical prognosis; Patients; Prevention; Prostate cancer; Quality of life; Retention; Risk factors; Schedules; Steroids; toxicity; Netherlands; dexamethasone; toxicity; prostate cancer; docetaxel; phase 1 study; hypersensitivity reactions; breast cancer; fluid retention syndrome
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15061691

There is little evidence that supports the registered high dose of dexamethasone used around docetaxel. However, this high dose is associated with considerable side effects. This study evaluates the feasibility of reducing the prophylactic oral dosage of dexamethasone around docetaxel infusion. Eligible patients had a histologically confirmed diagnosis of prostate or breast cancer and had received at least three cycles of docetaxel as monotherapy or combination therapy. Prophylactic dexamethasone around docetaxel infusion was administered in a de-escalating order per cohort of patients. Primary endpoint was the occurrence of grade III/IV fluid retention and hypersensitivity reactions (HSRs). Of the 46 enrolled patients, 39 were evaluable (prostate cancer ( = 25), breast cancer ( = 14). In patients with prostate cancer, the dosage of dexamethasone was reduced to a single dose of 4 mg; in patients with breast cancer, the dosage was reduced to a 3-day schedule of 4 mg-8 mg-4 mg once daily, after which no further reduction has been tested. None of the 39 patients developed grade III/IV fluid retention or HSR. One patient (2.6%) had a grade 1 HSR, and there were six patients (15.4%) with grade I or II edema. There were no differences in quality of life (QoL) between cohorts. It seems that the prophylactic dose of dexamethasone around docetaxel infusion can be safely reduced with respect to the occurrence of grade III/IV HSRs or the fluid retention syndrome.